Interactive value tools combine published research data, local patient- and sales data and health economic analysis into one easy-to-use tool.
Medaffcon’s interactive value tools combine published research data, local patient- and sales data and health economic analysis into one easy-to-use tool. All relevant data is presented in an understandable and practical manner. The data can be further extended with Medaffcon’s RWE studies and Fast Track data requests or the tool can be specifically tailored to present these results.
The aim is to provide a visually pleasant, interactive user experience and data formability according to user needs.
Interactive tools are especially popular in the customer interface where they can be used to support and adapt campaigns and research publications. The tools enable i.e.:
Medaffcon’s multifunctional team executes interactive tools for the needs of sales, marketing, medical and market access departments. Depending on the scope of the project, we utilize our extensive medical, health economic and data-analysis expertise.
Interactive tools are most commonly built using software such as Microsoft Excel or PowerBI but are also possible to implement using other alternatives.
The adoption of new diabetes medications in Finland was active between 2012 and 2019, according to an RWE (Real World Evidence) study published in May 2024. The study was conducted by Medaffcon in collaboration with the pharmaceutical company Sanofi.
In the coming years, breakthroughs in neurological and psychiatric drug research are expected to change treatment practices and significantly improve patients’ quality of life. Medaffcon is contributing to this development by conducting, for example, RWE studies (Real World Evidence).
Lung cancer is the leading cause of cancer deaths in Finland, with a particularly poor prognosis for non-small cell lung cancer (NSCLC). It is often diagnosed at an advanced stage when treatment options are limited. A recently published retrospective registry-based real-world evidence (RWE) study on KRAS-mutated NSCLC patients in Finland addressed this issue.
Sr. Scientific Advisor
RWE Lead
PhD
+358 50 345 2393
mariann.lassenius@medaffcon.fi
Mariann joined Medaffcon’s team in 2016 after finishing her PhD. The transition to real world evidence (RWE) research was a natural continuum to her previous research career. Through RWE studies, she has had the privilege to gain a broad insight into working with different stakeholders within the healthcare field. The vast proportion of her days goes towards interacting with clients, planning and performing RWE studies, and supporting Medaffcon’s RWE team. Subjects that keep her work interesting are the vast variability of customers and projects, problem-solving, and interacting with people.
“The number of RWE studies has increased since stakeholders within the healthcare industry have an increasing demand for knowledge-based decision making tools that need to be fulfilled. The future, therefore, has an ever-increasing emphasis on RWE”.
Biostatistician
Data Analysis Lead
MSc (Tech.)
+358 44 314 1597
iiro.toppila@medaffcon.fi
Iiro joined Medaffcon in March 2017 as a Biostatistician. For the preceding four years, he has worked as a research assistant in an academic study group, analyzing clinical and genetic patient data. Iiro holds a Master of Science degree in Technology in Bioinformation Technology.
Iiro’s strengths include his strong expertise in statistics and data-analysis, hands-on experience in working with sensitive patient data, and strong interdisciplinary communication skills with experts from various fields. In the field, he is particularly interested in the large data amounts made available with the revolution of technology and how the information received such data can potentially be utilized to draw concrete conclusions, both in order to understand the nature of diseases and to advance the goals of the pharmaceutical industry and patient treatment.
“Machine learning and AI-based solutions will have a major impact on the healthcare sector now and in the future. However, effectively utilizing the already collected and available health-data will have a higher importance in order to improve health-care”.